Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report

Abstract

We report here a case of alopecia probably caused by the fixed dose combination of doravirine/tenofovir disproxil fumarate/lamivudine (DOR/TDF/3TC) in a 46-year-old male living with HIV, previously treated with tenofovir disproxil fumarate and lamivudine-containing antiretroviral combinations. After having excluded other causes of hair loss such as sexually transmitted disease or drugs associated with alopecia, as well as poor immune-virologic conditions (i.e. low CD4⁺ cell count and/or high HIV viral load), a toxic effect of doravirine might be hypothesized. DOR/TDF/3TC was immediately stopped and rilpivirine plus tenofovir alafenamide fumarate/emtricitabine was started. Four weeks after changing the antiretroviral regimen, the patient reported signs of hypopigmented hair regrowth. The association between the episode of alopecia and DOR/TDF/3TC was scored as probable according to the Naranjo causality scale. We concluded that alopecia was probably related to DOR but whether it is self-limiting, cannot be predicted at this stage.

Keywords

ART (antiretroviral therapy) < other toxicity < other AIDS < viral disease

Get full access to this article

View all access options for this article.

References

Blevins

Hester

Chastain

, et al.

Doravirine: a return of the NNRTI class?

Ann Pharmacother 2020; 54: 64–74.

Doravirine-US Food and Drug Administration . Available at:, https://www.fda.gov/media/128270/download, (last access, January 1, 2022).

Doravirine . Prescribing Information. Available at:, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210807s003lbl.pdf (last access, January 1, 2022).

Woods

Foisy

. Antiretroviral-related alopecia in HIV-infected patients. Ann Pharmacother 2014; 48: 1187–1193.

El Zein

Tabaja

Kanj

, et al. Alopecia after switch to tenofovir alafenamide in 6 african american women. Open Forum Infect Dis 2019; 6: ofz278.

Kim

Shin

. Alopecia areata associated with abacavir therapy. Infect Chemother 2014; 46: 103–105.

Colombier

Molina

. Doravirine: a review. Curr Opin HIV AIDS 2018; 13: 308–314.

U.S. Food and Drug Administration . FDA Adverse Event Reporting System (FAERS), Silver Spring, MD: Food and Drug Administration. www.fda.gov/drugs/fda-adverse-event-reporting-system-faers (last access, January 1, 2022).